Valuation: Tyra Biosciences, Inc.

Market Cap 1.33B 1.18B 1.1B 994M 1.87B 126B 1.9B 13.16B 5.17B 65.92B 4.99B 4.88B 210B P/E 2026 *
-7.7x
P/E 2027 * -7.38x
Enterprise Value 839M 747M 692M 627M 1.18B 79.49B 1.2B 8.31B 3.26B 41.6B 3.15B 3.08B 133B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.57%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tyra Biosciences, Inc.

1 day+5.84%
1 week+10.29%
Current month-6.40%
1 month-20.44%
3 months-34.08%
6 months-40.44%
Current year-22.14%
1 week 18.26
Extreme 18.26
20.58
1 month 18.25
Extreme 18.25
26.43
Current year 18.25
Extreme 18.25
40.65
1 year 13.35
Extreme 13.35
40.65
3 years 6.42
Extreme 6.42
40.65
5 years 4.93
Extreme 4.93
40.65
10 years 4.93
Extreme 4.93
40.65
Manager TitleAgeSince
Chief Operating Officer 51 2018-10-31
Chief Executive Officer 46 2018-10-31
Director of Finance/CFO 69 2022-12-31
Director TitleAgeSince
Chairman 58 2019-02-28
Director/Board Member 46 2018-08-01
Director/Board Member 40 2019-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/15/26 Free

Chief Financial Officer

951 0.0014%
9/15/26 Free

Founder

864 0.0013%
9/15/26
RA Capital Management LP
BuyCompany 9,078,529 13.2040%
Change 5-day change 1-year change 3-year change Capi.($)
+5.84%+10.29%+36.28%+45.69% 1.33B
+0.79%-6.46%+52.86%+71.34% 65.83B
+1.92%+8.89%+12.90%+82.75% 51.87B
+6.91%+8.57%+6.88%+72.12% 51.2B
+0.74%+2.75%+26.31%+45.29% 43.76B
+3.87%+10.15%+20.69%+132.73% 42.09B
+7.91%+4.30%+263.91%+602.72% 39.04B
-0.40%+9.42%+18.44%+59.06% 34B
+3.84%-4.94%+42.35%+8.92% 25.2B
+2.36%+4.62%+24.20%+31.02% 22.8B
Average +3.38%+1.47%+50.48%+115.16% 37.71B
Weighted average by Cap. +3.06%+1.82%+50.70%+124.04%

Financials

2026 *2027 *
Net sales - -
Net income -177M -158M -146M -133M -249M -16.8B -253M -1.76B -690M -8.79B -665M -651M -28.05B -209M -186M -173M -156M -294M -19.82B -299M -2.07B -813M -10.37B -785M -768M -33.08B
Net Debt -491M -437M -405M -367M -689M -46.48B -701M -4.86B -1.91B -24.32B -1.84B -1.8B -77.59B -323M -287M -266M -241M -454M -30.59B -461M -3.2B -1.26B -16.01B -1.21B -1.19B -51.07B
Projected Income Statement - Annual - Tyra Biosciences, Inc.
Logo Tyra Biosciences, Inc.
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma).
Employees
87
Date Price Change Volume
26-10-20 US$20.47 +5.84% 607,588
26-10-19 US$19.34 +4.43% 871,846
26-10-16 US$18.52 -2.73% 648,973
26-10-15 US$19.04 +1.82% 418,028
26-10-14 US$18.70 +0.75% 483,997
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Tyra Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
20.48USD
Average target price
47.45USD
Spread / Average Target
+131.71%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Tyra Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. TYRA Stock